All Merck Articles
Vista Alert: Indaptus Therapeutics Offers Novel Immunotherapy Decoy20 Cancer Treatment Progress Update – $INDP $MRK $NVS $PFE $XBI
Decoy20 represents a novel approach to cancer immunotherapy. Unlike current treatments that target specific immune pathways, Decoy20 aims to activate a broad antitumor response from both innate and adaptive immune systems. Composed of attenuated and killed non-pathogenic Gram-negative bacteria, Deco...
Sep 08, 2024
View Article
Pharma’s Evolving 2024 Acquisition Spree – $ABBV $EPRX $GILD $JNJ $LLY $MRK $NVS $VRTX
Based on reports from The Wall Street Journal, major pharmaceutical companies are shifting their focus to smaller acquisitions in 2024, with all 17 deals announced in the first half of the year valued at $5 billion or less, reflecting a changing regulatory landscape and a more selective approach to ...
Aug 21, 2024
View Article
Merck’s Prevymis Earns European Approval For Kidney Transplant Recipient Care – $MRK $DIA $IBB $LTRN
Reportedly, Merck & Co., Inc. (MRK) announced that the European Union medicines regulator has recommended granting marketing authorization for their medication, Prevymis, aimed at treating a specific infection in adult kidney transplant recipients at a high risk. Furthermore, the Committee for M...
Oct 18, 2023
View Article
Merck Exceeds Revenue Estimates With Strong Sales Of Keytruda & Gardasil In Q2 2023 – $MRK $DIA $IBB $LTRN
Reportedly, Merck & Co., Inc. (MRK) second-quarter revenue exceeded estimates, primarily driven by strong sales of its cancer drug Keytruda and HPV vaccine Gardasil. However, the company swung to a net loss of $5.98 billion, or $2.35 per share, from the previous year's net income of $3.94 billio...
Sep 18, 2023
View Article
Merck Approves $0.73 Per Share Dividend For Q3 2023 – $MRK $DIA $IBB $INVO
As per reports, the board of Merck & Co., Inc. (MRK) announced its quarterly dividend for the third quarter of 2023. The board has authorised a dividend of $0.73 per share for the common stock. Shareholders who are officially listed as such by the end of business on June 15, 2023, will be eligib...
Jun 16, 2023
View Article
Merck’s Q1 2023 Sales & Earnings Call On April 27 – $MRK $DIA $IBB $INVO
Merck & Co., Inc. (MRK) will host a conference call on April 27, 2023 at 9:00 a.m. ET for institutional investors and analysts to discuss the company's sales and earnings for the first quarter. The call will feature an overview of the quarter's performance by company executives. A live audio web...
Apr 04, 2023
View Article
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
